Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan

被引:28
|
作者
Gelhorn, Heather L. [1 ]
Bacci, Elizabeth D. [2 ]
Poon, Jiat Ling [1 ]
Boye, Kristina S. [3 ]
Suzuki, Shuichi [4 ]
Babineaux, Steven M. [3 ]
机构
[1] Evidera, Outcomes Res, Bethesda, MD USA
[2] Evidera, Seattle, WA USA
[3] Eli Lilly & Co, Global Patient Outcomes & Real World Evidence, Indianapolis, IN 46285 USA
[4] Eli Lilly Japan, Med Dev Unit Japan, Kobe, Hyogo, Japan
来源
PATIENT PREFERENCE AND ADHERENCE | 2016年 / 10卷
关键词
discrete choice experiment; patient's preference; type; 2; diabetes; GLP-1 receptor agonists; willingness to inject; DISCRETE-CHOICE EXPERIMENT; LIRAGLUTIDE; MELLITUS;
D O I
10.2147/PPA.S109289
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients' preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus (T2DM) in Japan. Methods: In Japan, patients with self-reported T2DM and naive to treatment with self-injectable medications were administered a DCE through an in-person interview. The DCE examined the following six attributes of T2DM treatment, each described by two levels: "dosing frequency", "hemoglobin A1c change", "weight change", "type of delivery system", "frequency of nausea", and "frequency of hypoglycemia". Part-worth utilities were estimated using logit models and were used to calculate the relative importance (RI) of each attribute. A chi-square test was used to determine the differences in preferences for the dulaglutide versus liraglutide profiles. Results: The final evaluable sample consisted of 182 participants (mean age: 58.9 [standard deviation = 10.0] years; 64.3% male; mean body mass index: 26.1 [standard deviation = 5.0] kg/m(2)). The RI values for the attributes in rank order were dosing frequency (44.1%), type of delivery system (26.3%), frequency of nausea (15.1%), frequency of hypoglycemia (7.4%), weight change (6.2%), and hemoglobin A1c change (1.0%). Significantly more participants preferred the dulaglutide profile (94.5%) compared to the liraglutide profile (5.5%; P<0.0001). Conclusion: This study elicited the preferences of Japanese T2DM patients for attributes and levels representing the actual characteristics of two existing glucagon-like peptide-1 receptor agonists. In this comparison, dosing frequency and type of delivery system were the two most important characteristics, accounting for >70% of the RI. These findings are similar to those of a previous UK study, providing information about patients' preferences that may be informative for patient-clinician treatment discussions.
引用
收藏
页码:1337 / 1348
页数:12
相关论文
共 50 条
  • [1] Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naive type 2 diabetes patients in the UK
    Gelhorn, Heather L.
    Poon, Jiat-Ling
    Davies, Evan W.
    Paczkowski, Rosirene
    Curtis, Sarah E.
    Boye, Kristina S.
    PATIENT PREFERENCE AND ADHERENCE, 2015, 9 : 1611 - 1622
  • [2] Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
    Mosenzon, Ofri
    Schechter, Meir
    Leibowitz, Gil
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 347 - 360
  • [3] Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes
    Tran, Kelvin Lingjet
    Park, Young In
    Pandya, Shalin
    Muliyil, Navin John
    Jensen, Brandon David
    Huynh, Kovin
    Nguyen, Quang T.
    AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (04) : 178 - 187
  • [4] Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes
    Storgaard, Heidi
    Cold, Frederik
    Gluud, Lise L.
    Vilsboll, Tina
    Knop, Filip K.
    DIABETES OBESITY & METABOLISM, 2017, 19 (06) : 906 - 908
  • [5] It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
    Oberle, Megan M.
    Kelly, Aaron S.
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [6] Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
    Lund, Asger
    Knop, Filip K.
    Vilsboll, Tina
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (05) : 407 - 414
  • [7] Patients' Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
    Banjara, Bidur
    Poudel, Nabin
    Garza, Kimberly B.
    Westrick, Salisa
    Whitley, Heather P.
    Redden, David
    Ngorsuraches, Surachat
    PATIENT PREFERENCE AND ADHERENCE, 2022, 16 : 3415 - 3428
  • [8] Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
    Lovshin, Julie A.
    CANADIAN JOURNAL OF DIABETES, 2017, 41 (05) : 524 - 535
  • [9] The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
    Yin, Win L.
    Bain, Steve C.
    Min, Thinzar
    DIABETES THERAPY, 2020, 11 (04) : 835 - 844
  • [10] Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naive Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study
    Qin, Lei
    Chen, Stephanie
    Flood, Emuella
    Shaunik, Alka
    Romero, Beverly
    de la Cruz, Marie
    Alvarez, Cynthia
    Grandy, Susan
    DIABETES THERAPY, 2017, 8 (02) : 321 - 334